journal article·2023-12Open access

Monitoring Melanoma Responses to STING Agonism and Focused Ultrasound Thermal Ablation Using Microneedles and Ultrasensitive Single Molecule Arrays

Daniel Dahis, Michelle Z. Dion, Alexander M. Cryer, Pere Dosta, Tal Gilboa, Mariana Alonso, Michael Lewandowski, Núria Puigmal, Gonzalo Muñoz Taboada, Haim Azhari, Rushdy Ahmad, David R. Walt, Natalie Artzi

Advanced Functional Materials· Volume 33· Issue 50

Abstract

Abstract Real‐time monitoring of immune state and response to therapy can provide a means to stratify patients and increase the number of responders who will benefit from approved and emerging immunotherapies. The accessibility of immune cells in the skin provides an opportunity for local immune modulation as well as for noninvasive sampling of disease biomarkers in the skin interstitial fluid (ISF). Here, a monitoring strategy for melanoma immunotherapy is investigated by longitudinal sampling of biomarkers in the skin ISF using Hyaluronic acid (HA)‐based microneedles (MNs). Focused ultrasound ablation and delivery of nanoparticulate stimulator of interferon genes agonist are used as model immunotherapies. It is shown that this combination therapy induces potent inflammatory responses in a melanoma mouse model, promoting tumor elimination and immune memory formation. Indeed, quantifying soluble, protein‐based biomarkers following therapy using conventional immunoassay reveals a pronounced proinflammatory program in the tumor. However, conventional assays fail to detect the low concentration of biomarkers in plasma and in MN‐sampled ISF. It is shown that ultrasensitive single molecule arrays (Simoa) effectively detected proinflammatory biomarkers that are upregulated in response to the therapy in MN‐sampled ISF, in plasma, and in tumors, supporting the feasibility of monitoring melanoma immunotherapy using MNs.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Advanced Biosensing Techniques and Applications · Microfluidic and Bio-sensing Technologies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Technion Institute of Technology Haifa 320003 Israel

Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge MA 02139 USA

Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA

Wyss Institute for Biologically‐Inspired Engineering Harvard University Boston MA 02115 USA

Harvard‐MIT Division of Health Sciences & Technology, Massachusetts Institute of Technology, Cambridge, MA, USA Cambridge 02139 United States

Department of Pathology, Brigham and Women's Hospital Harvard Medical School Boston Boston MA 02115 USA

Broad Institute of Harvard and MIT Cambridge MA 02139 USA

Funding

European Association for Cancer Research · United States - Israel Binational Science Foundation

References (100+)

Show source-provided references
1. 10.1101/cshperspect.a01538810.1101/cshperspect.a015388 ↗
2. 10.15586/CODON.CUTANEOUSMELANOMA.2017.CH110.15586/CODON.CUTANEOUSMELANOMA.2017.CH1 ↗
3. 10.1038/nrclinonc.2017.4310.1038/nrclinonc.2017.43 ↗
4. 10.1056/NEJMoa191083610.1056/NEJMoa1910836 ↗
5. 10.1586/14737140.2015.107486210.1586/14737140.2015.1074862 ↗
6. 10.1186/s40425-018-0479-710.1186/s40425-018-0479-7 ↗
7. 10.1200/EDBK_24083710.1200/EDBK_240837 ↗
8. 10.1016/j.ctrv.2018.09.00510.1016/j.ctrv.2018.09.005 ↗
9. 10.2147/CMAR.S26977310.2147/CMAR.S269773 ↗
10. 10.1080/2162402X.2020.173194210.1080/2162402X.2020.1731942 ↗
11. 10.1038/nature2207910.1038/nature22079 ↗
12. 10.1007/s00262-018-2229-610.1007/s00262-018-2229-6 ↗
13. 10.1007/s11307-017-1060-310.1007/s11307-017-1060-3 ↗
14. 10.2967/jnumed.114.15333810.2967/jnumed.114.153338 ↗
15. 10.3390/ijms2218971410.3390/ijms22189714 ↗
16. 10.1038/s41416-020-01047-510.1038/s41416-020-01047-5 ↗
17. 10.1126/scitranslmed.300709410.1126/scitranslmed.3007094 ↗
18. 10.1038/s42003-018-0170-z10.1038/s42003-018-0170-z ↗
19. 10.1038/s41587-019-0040-310.1038/s41587-019-0040-3 ↗
20. 10.1002/pmic.20060093810.1002/pmic.200600938 ↗
21. 10.1038/s41551‐022‐00998‐910.1038/s41551‐022‐00998‐9 ↗
22. 10.2174/15733990878529440610.2174/157339908785294406 ↗
23. 10.3390/s2023692510.3390/s20236925 ↗
24. Tumor interstitial fluid: misconsidered component of the internal milieu of a solid tumor. | Semantic Scholar.https://www.semanticscholar.org/paper/Tumor‐interstitial‐fluid%3A‐misconsidered‐component‐a‐Freitas‐Baronzio/e1ba46ab3c212ea3ab53fb66f0709ff14ec83b05(accessed: 30th June 2022).
25. 10.1186/1755-1536-3-1210.1186/1755-1536-3-12 ↗
26. Agache P. G. · 2011
27. 10.1371/journal.pone.001921710.1371/journal.pone.0019217 ↗
28. 10.1021/acs.jproteome.9b0077010.1021/acs.jproteome.9b00770 ↗
29. 10.1001/jamadermatol.2020.267510.1001/jamadermatol.2020.2675 ↗
30. 10.1038/jid.1968.1510.1038/jid.1968.15 ↗
31. 10.1016/j.ejps.2008.09.00210.1016/j.ejps.2008.09.002 ↗
32. 10.1177/009127000731215210.1177/0091270007312152 ↗
33. 10.1002/adfm.20200059110.1002/adfm.202000591 ↗
34. 10.1016/j.jconrel.2016.12.00710.1016/j.jconrel.2016.12.007 ↗
35. 10.1126/scitranslmed.aaw028510.1126/scitranslmed.aaw0285 ↗
36. 10.1002/adma.20170224310.1002/adma.201702243 ↗
37. 10.1038/s41378-020-00206-110.1038/s41378-020-00206-1 ↗
38. 10.1038/s41551-020-00672-y10.1038/s41551-020-00672-y ↗
39. Puigmal N. · Adv. Funct. Mater. · 2021 · 31
40. 10.7150/thno.7396610.7150/thno.73966 ↗
41. 10.1038/s41571-021-00588-910.1038/s41571-021-00588-9 ↗
42. 10.1177/221106821558958010.1177/2211068215589580 ↗
43. 10.1038/nbt.164110.1038/nbt.1641 ↗
44. 10.1039/C5AN01238D10.1039/C5AN01238D ↗
45. 10.1126/sciadv.abo528510.1126/sciadv.abo5285 ↗
46. 10.1016/j.jconrel.2020.12.04010.1016/j.jconrel.2020.12.040 ↗
47. 10.1186/s12951-021-01226-310.1186/s12951-021-01226-3 ↗
48. 10.3390/cancers1311269510.3390/cancers13112695 ↗
49. 10.1016/j.diii.2018.03.00110.1016/j.diii.2018.03.001 ↗
50. 10.1007/s00262-016-1891-910.1007/s00262-016-1891-9 ↗
51. 10.7150/thno.2122510.7150/thno.21225 ↗
52. 10.1186/s40349-016-0046-y10.1186/s40349-016-0046-y ↗
53. 10.7150/thno.2561310.7150/thno.25613 ↗
54. 10.7150/thno.3757410.7150/thno.37574 ↗
55. 10.1126/scitranslmed.aaa430610.1126/scitranslmed.aaa4306 ↗
56. 10.1038/s41563-022-01251-z10.1038/s41563-022-01251-z ↗
57. 2022 21 710.
58. 10.1038/s41565-018-0342-510.1038/s41565-018-0342-5 ↗
59. 10.1016/j.celrep.2015.04.03110.1016/j.celrep.2015.04.031 ↗
60. 10.1038/s41565‐023‐01447‐710.1038/s41565‐023‐01447‐7 ↗
61. 10.1158/0008-5472.CAN-14-361910.1158/0008-5472.CAN-14-3619 ↗
62. 10.1177/205101361350198810.1177/2051013613501988 ↗
63. 10.1038/s41565-018-0342-510.1038/s41565-018-0342-5 ↗
64. 10.1126/sciadv.aay924910.1126/sciadv.aay9249 ↗
65. 10.1093/clinchem/hvab25110.1093/clinchem/hvab251 ↗
66. 10.1002/ange.20211070210.1002/ange.202110702 ↗
67. 10.1002/adhm.20200111110.1002/adhm.202001111 ↗
68. 10.1038/sj.jid.570122310.1038/sj.jid.5701223 ↗
69. 10.3390/ijms2003053810.3390/ijms20030538 ↗
70. 10.1186/s12951-021-01087-w10.1186/s12951-021-01087-w ↗
71. 10.1016/j.jss.2008.07.03410.1016/j.jss.2008.07.034 ↗
72. 10.1097/00000658-200207000-0001710.1097/00000658-200207000-00017 ↗
73. 10.1126/scitranslmed.aaa430610.1126/scitranslmed.aaa4306 ↗
74. 10.1038/nrc367210.1038/nrc3672 ↗
75. 10.18632/oncotarget.2788610.18632/oncotarget.27886 ↗
76. 10.1172/jci.insight.9052110.1172/jci.insight.90521 ↗
77. 10.1136/jitc-2020-00100810.1136/jitc-2020-001008 ↗
78. 10.1016/j.celrep.2019.09.06510.1016/j.celrep.2019.09.065 ↗
79. 10.1038/nri384510.1038/nri3845 ↗
80. 10.1002/adbi.20190023710.1002/adbi.201900237 ↗
81. 10.1038/s41598-020-80135-110.1038/s41598-020-80135-1 ↗
82. 10.1136/jitc-2020-00100810.1136/jitc-2020-001008 ↗
83. 10.1155/2011/16025010.1155/2011/160250 ↗
84. 10.1016/j.lers.2018.01.00110.1016/j.lers.2018.01.001 ↗
85. 10.1073/pnas.181226611510.1073/pnas.1812266115 ↗
86. 10.1038/s41598-020-80135-110.1038/s41598-020-80135-1 ↗
87. 10.1148/radiol.201515116610.1148/radiol.2015151166 ↗
88. 10.1136/jitc-2020-00100810.1136/jitc-2020-001008 ↗
89. 10.1038/nrrheum.2010.4610.1038/nrrheum.2010.46 ↗
90. 10.1016/bs.mie.2019.06.00110.1016/bs.mie.2019.06.001 ↗
91. 10.1007/978-1-62703-589-7_1610.1007/978-1-62703-589-7_16 ↗
92. 10.1172/JCI7991510.1172/JCI79915 ↗
93. 10.4049/jimmunol.180163410.4049/jimmunol.1801634 ↗
94. 10.1016/j.jconrel.2020.11.01710.1016/j.jconrel.2020.11.017 ↗
95. 10.1136/jitc-2020-00217110.1136/jitc-2020-002171 ↗
96. 10.1111/bjd.1415510.1111/bjd.14155 ↗
97. 10.7554/eLife.0738310.7554/eLife.07383 ↗
98. 10.1016/j.cllc.2018.04.01410.1016/j.cllc.2018.04.014 ↗
99. 10.1158/2326-6066.CIR-16-032910.1158/2326-6066.CIR-16-0329 ↗
100. 10.1158/1078-0432.CCR-18-385810.1158/1078-0432.CCR-18-3858 ↗